Altimmune (ALT) Non-Current Deffered Revenue (2010 - 2018)
Altimmune (ALT) reported Non-Current Deffered Revenue of $1.0 million for Q4 2018, up 170.59% year-over-year from $386489.0 in Q4 2017, and up 622.05% on a QoQ basis from $144838.0 in Q3 2018.
Altimmune (ALT) has 5 years of Non-Current Deffered Revenue data on file, last reported at $1.0 million in Q4 2018.
- Quarterly Non-Current Deffered Revenue rose 170.59% year-over-year to $1.0 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $1.0 million (up 170.59% YoY) and the FY2018 annual result came in at $1.0 million, up 170.59% from the prior year.
- Non-Current Deffered Revenue grew to $1.0 million in Q4 2018 per ALT's latest filing, from $144838.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $1.1 million in Q1 2018 and bottomed at $1591.0 in Q3 2017.
- The 3-year median for Non-Current Deffered Revenue is $164604.5 (2016), against an average of $379016.9.
- The widest annual swing landed in 2017, when Non-Current Deffered Revenue surged 115.41%; it then surged 9003.58% in 2018.
- Tracing ALT's Non-Current Deffered Revenue over 3 years: stood at $179424.0 in 2016, then surged by 115.41% to $386489.0 in 2017, then soared by 170.59% to $1.0 million in 2018.
- Per Business Quant, the three latest ALT Non-Current Deffered Revenue figures stand at $1.0 million (Q4 2018), $144838.0 (Q3 2018), and $149785.0 (Q2 2018).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 1.05 Mn |
| Sep 30, 2018 | 144,838.00 |
| Jun 30, 2018 | 149,785.00 |
| Mar 31, 2018 | 1.12 Mn |
| Dec 31, 2017 | 386,489.00 |
| Sep 30, 2017 | 1,591.00 |
| Jun 30, 2017 | 6,366.00 |
| Dec 31, 2016 | 179,424.00 |
| Dec 31, 2011 | 449,709.00 |
| Sep 30, 2011 | 454,093.00 |
| Jun 30, 2011 | 458,477.00 |
| Dec 31, 2010 | 461,858.00 |